title: Effect of losartan on nocturnal blood pressure in patients with stroke: comparison with angiotensin converting enzyme inhibitor.
abstract: BACKGROUND
  Treatment of nocturnal hypertension has been reported to be beneficial for primary and secondary prevention of stroke. We compared the effects of angiotensin II antagonist (losartan) and angiotensin converting enzyme inhibitor (quinapril) on nocturnal blood pressure (BP) and sympathetic nervous activity in patients with hypertension and stroke.
  
  
  METHODS
  According to a prospective, randomized, cross-over design, 30 hypertensive patients with a previous history of stroke (25 hemorrhage, 5 infarction) were assigned randomly to receive losartan (50 mg) or quinapril (10 mg) once daily for 4 weeks. The patients were switched to the alternative regimen for an additional 4-week period. In the last week of each treatment, 24-h ambulatory BP monitoring was performed every 30 min, and 24-h urine was collected for the measurement of catecholamine.
  
  
  RESULTS
  Neither systolic nor diastolic BP during daytime differed between losartan and quinapril treatments, but those during nighttime were lower with losartan treatment than with quinapril treatment. The nocturnal decreases in systolic and diastolic BP were both greater with losartan treatment than with quinapril treatment (systolic BP: 6.1% +/- 5.9% v 2.5% +/- 6.9%, diastolic BP: 6.4% +/- 6.5% v 3.3% +/- 7.8%, both P <.05). The nocturnal decrease in urinary norepinephrine excretion was greater with losartan treatment than with quinapril treatment (52.8% +/- 9.7% v 42.8% +/- 17.2%, P <.05).
  
  
  CONCLUSIONS
  Losartan enhances the nocturnal decrease in ambulatory BP compared with that of quinapril in patients with a previous history of stroke presumably by way of the suppression of nocturnal sympathetic nervous activity.
authors.affiliation: Department of Internal Medicine, Reimeikyo Rehabilitation Hospital, Ikarigaseki, Japan.
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Okuguchi
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Osanai
authors.forename: Naoto
authors.initials: N
authors.lastname: Fujiwara
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kato
authors.forename: Norifumi
authors.initials: N
authors.lastname: Metoki
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Konta
authors.forename: Ken
authors.initials: K
authors.lastname: Okumura
mesh_terms: D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002940:Circadian Rhythm; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007546:Isoquinolines / Q000627:therapeutic use*; D019808:Losartan / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000077583:Quinapril; D020521:Stroke / Q000150:complications / Q000188:drug therapy*; D044005:Tetrahydroisoquinolines; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D007546:Isoquinolines; D044005:Tetrahydroisoquinolines; D019808:Losartan; D000077583:Quinapril